New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease

Table 2

Long term effects of SGLT2 inhibitors as approved glucose-lowering agents.

Inhibitor	Diabetes	Effects	References
Canagliflozin	Type 2	Reduces GFR, , BW, BP, FPG.	[266, 267]
Dapagliflozin	Type 2	Reduces GFR, BP, BW, , albumin and stabilizes insulin dosing.	[268–272]
Empagliflozin	Type 1; Type 2	Reduces GFR, plasma NO, , arterial stiffness, heart failure hospitalization, cardiovascular death.	[207, 273–275]
Ipragliflozin	Type 2	Reduces , BW, FPG and improves liver function and lipid profile.	[276–278]

Glycated haemoglobin, , glomerular filtration rate, GFR, fasting plasma glucose, FPG, body weight, BW, blood pressure, BP, and nitric oxide, NO.